Sunday, April 20, 2014

Lisa Emrich's Posts

Hot Topics and MS Research News for March 2014

Statin Drugs Reduce Brain Atrophy in Secondary Progressive MS Statins, or cholesterol-lowering, have been studied in multiple sclerosis for years with varying results.  In a recent phase 2 study, researchers noted a 43% reduced annualized rate of brain atrophy (shrinkage) in secondary-progressive MS (SPMS) patients (n=140) taking 80mg... Read moreChevron

Inspirational MS Stories featured in SwimForMS campaign, sponsored by MSAA and Genzyme

Staying active and engaging in regular exercise are important activities that promote healthy living, especially for persons who are faced with physically challenging diseases such as multiple sclerosis or rheumatoid arthritis.  The benefits of exercise extend beyond the physical into the mental and emotional health of the individual. ... Read moreChevron

Tisch MS Research Center Launches Indiegogo Campaign to Raise $300,000 for Stem Cell Trial

Last week more than 300 MS Activists visited their elected officials on Capitol Hill to ask for increased funding for research at the National Institute of Health (NIH) and the Congressionally Directed Medical Research Program (CDMRP) which have been instrumental in conducting vital research into the causes, treatments, and understanding of... Read moreChevron

MS Awareness Month 2014 and Telling Your Story

Each March is MS Awareness Month in the US and March 3-9, 2014, is MS Awareness Week!!  It is a great time to tell your story to educate and spread awareness of the disease and to bring hope and inspiration (provide comfort and courage) to others whose lives have been touched by multiple sclerosis. Next week in Washington, DC, hundreds of MS... Read moreChevron

Hot Topics and MS Research News for February 2014

Aubagio approved in the UK for MS: Previously approved by the FDA in September 2012, the oral MS drug teriflunomide (Aubagio) has now been accepted for use in the United Kingdom (UK) National Health Service by the National Institute for Health and Care Excellence (NICE) for the treatment of patients with relapsing-remitting MS. ... Read moreChevron